GetTopicDetailResponse(id=200212e2546f, topicName=雙免疫療法, introduction=, content=食管胃結(jié)合部腺癌 雙免疫療法, image=null, comments=0, allHits=169, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sun May 25 00:07:14 CST 2025, time=2025-05-25, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=504917, tagList=[TagDto(tagId=504917, tagName=雙免疫療法)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2266534, encodeId=2ad52266534bf, content=<a href='/topic/show?id=d694109631a7' target=_blank style='color:#2F92EE;'>#食管胃結(jié)合部腺癌#</a> <a href='/topic/show?id=200212e2546f' target=_blank style='color:#2F92EE;'>#雙免疫療法#</a>, objectTitle=無需化療，客觀緩解率達62%，無進展生存期近14個月！JCO：雙免疫療法或為胃癌一線治療新選擇, objectType=article, longId=878662, objectId=65798e8662a2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240508/1715158312120_92910.png, objectUrl=/article/show_article.do?id=65798e8662a2, replyNumber=0, likeNumber=34, createdTime=2025-05-25, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=65798e8662a2, moduleTitle=無需化療，客觀緩解率達62%，無進展生存期近14個月！JCO：雙免疫療法或為胃癌一線治療新選擇, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=65798e8662a2)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-05-25發(fā)表于上海
